VANCOUVER, June 8 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has elected its 2009 Board of Directors at its recent Annual General Meeting. The six-member Board consists of: Dr. James McEwen (Chairman), Dr. Heiner Dreismann, Mr. Jim Heppell, Mr. Amos Michelson, Dr. Bradley Popovich and Mr. Patrick Terry.
"With the global expertise in molecular diagnostics, commercialization and personalized medicine experience that is prevalent on our Board, Sirius will remain on course to successfully bring our first companion diagnostic, intended to assess responsiveness to recombinant human activated Protein C, to market. Under this leadership, Sirius will be situated to become a worldwide participant in the growing field of companion diagnostics and personalized medicine," stated Dr. Popovich, President and CEO of Sirius Genomics.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
|SOURCE Sirius Genomics Inc.|
Copyright©2009 PR Newswire.
All rights reserved